Coign Capital Advisors LLC Invests $651,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Coign Capital Advisors LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,248 shares of the medical equipment provider’s stock, valued at approximately $651,000.

Other large investors have also recently bought and sold shares of the company. Atala Financial Inc bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $25,000. Hurley Capital LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at about $28,000. Berbice Capital Management LLC bought a new stake in Intuitive Surgical during the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $28,000. Finally, Summit Securities Group LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $489.52 on Friday. The firm’s 50 day simple moving average is $534.44 and its 200 day simple moving average is $532.30. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The company has a market capitalization of $174.36 billion, a price-to-earnings ratio of 76.37, a P/E/G ratio of 5.85 and a beta of 1.55.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Brian Edward Miller sold 8,900 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the sale, the executive vice president now owns 5,758 shares of the company’s stock, valued at $2,793,033.06. This trade represents a 60.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,754 shares of company stock valued at $17,691,621. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of recent analyst reports. CICC Research started coverage on Intuitive Surgical in a report on Monday, January 27th. They set a “neutral” rating and a $550.00 price target for the company. Leerink Partners raised their target price on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Truist Financial decreased their price objective on shares of Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Raymond James boosted their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Finally, Citigroup increased their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $611.86.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.